T-REGULATORY CELL KINETICS FOR PATIENTS RECEIVING ALEMTUZUMAB AND UNDERGOING STEM CELL TRANSPLANTATION FROM HLA MISMATCHED-RELATED OR ONE ANTIGEN MISMATCHED-UNRELATED DONORS.
Phase of Trial: Phase IV
Latest Information Update: 12 Jul 2013
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Cytarabine; Mesna; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease; Hodgkin's disease; Leukaemia; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms REGALE
- 01 May 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Mar 2013 Planned End Date changed from 1 Dec 2015 to 1 May 2013 as reported by ClinicalTrials.gov.
- 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.